In a recent pooled analysis of breast cancer data from up to 12 case -control studies from the Breast Cancer Association Consortium ( 1 ), five of 16 common single-nucleotide polymorphisms (SNPs) were associated with modest increases in risk. The authors interpreted their findings, with P values ranging from .06 to .0088, as failing to meet a level of statistical significance appropriate to genetic association studies. There were no associations for the other SNPs evaluated.
To us, these analyses and interpretation represent a growing divergence in perspective between investigators approaching disease from a statistical genetics viewpoint and those approaching it from a molecular epidemiologic viewpoint. Carcinogenesis is a dynamic process, usually the result of both exogenous and endogenous exposures, and we would not expect, for most pathways, to observe main effects for common genetic variants without consideration of relevant exposures. Moreover, because of the complex nature of carcinogenesis pathways, it is unlikely that a SNP in one single low-penetrance gene alone would be associated with an increase in cancer risk, without consideration of potential interactions with other polymorphic genes.
Genetic processes, and interactions with exposures, are far from simple. In addi tion to SNPs modifying risk associated with exposures, the impact of exposures on relationships between genetic variants and phenotype, through enzyme induction or inhibition, must also be considered. For example, effects of dietary exposures on relationships between catalase genotypes and enzyme activity have been demonstrated ( 2 ) . Although genotype predicted phenotype overall, relationships varied by levels of fruit and vegetable consumption, with genotype/phenotype correspondence only among consumers of low levels of fruits and vegetables, suggesting feedback mechanisms. Similarly, in a study of glutathione peroxidase genotype, erythrocyte activity, and breast cancer risk ( 3 ), although genotype predicted glutathione peroxidase activity overall, relationships between genotype and activity were modifi ed by alcohol consumption and smoking, with changes in activity according to levels of exposure varying by genotypes. These data illustrate the dynamic biologic systems in which the effects of SNPs on cancer risk are evaluated. Genotypes are not static variables, and the ultimate impact of SNPs on phenotype, and, more important, on cancer risk, will be modifi ed by exogenous and endogenous exposures.
Accumulating evidence illustrates the importance of exposures for breast cancer risk. It is notable that cancer rates are rising in Japan with westernization and that migrants to the United States from low-risk countries have increased breast cancer risk with subsequent generations ( 4 ). Clearly, genes are not changing; rather, lifestyle factors, perhaps interacting with genetics, are likely the cause of these rising cancer rates. The consortia authors noted heterogeneity in results among the pooled studies and commented that it is "likely due to some unexplained artifact" and that "it seems unlikely that there are associations in one population and not others." We would argue that, when examining the effects of genotypes without consideration of other exposures, it is highly likely that results from different populations would in fact differ, if there are important differences in the relevant exposures in the populations. For example, results from assessment of the main effects of alcohol dehydrogenase 1C (ADHC1), which is involved in metabolism of alcohol, would likely vary widely if one population included a large proportion of heavy consumers of alcoholic beverages and the other did not.
In summary, examination of common single SNPs in the absence of data on exposures, and expectations to see main effects, may not be appropriate. We suggest that considerable caution be exercised in the interpretation of main effects of common polymorphisms on risk of cancer. Genome-wide association studies are now yielding results and offer promise for identifi cation of genetic variants that may play a role in cancer risk. However, null results from such studies will only mean that the gene, in and of itself, is not associated with cancer risk and should not rule out further investigation of the effects of the genetic variants in modifying relationships between exposures and cancer risk.
The Breast Cancer Association Consortium did a remarkable job of pooling data from various studies to investigate the association of 16 single-nucleotide polymorphisms (SNPs) and breast cancer ( 1 ). The result was no association between the 16 SNPs and cancer after an adjustment for the type I error with 16 tests ( 2 ), although one could argue for a much more stringent adjustment based on the type I error needed for a low false-positive report probability ( 3 , 4 ) . Two competing conclusions can be drawn. One is that methods building on this approach should be applied to more genes and that it is only a matter of time before a confi rmed discovery of a true association will be made. The opposite conclusion is that the results of no association support other evidence of very weak or no association between common genetic variants and cancer ( 4 ), including 1) studies showing that many cancers arise from defects in communication between stromal and parenchymal cells ( 5 ), rather than mutations in parenchymal cells; 2) migration studies that fi nd that populations moving from one country to another generally experience the cancer rates of the new country within a generation or two ( 6 ), which is too soon to be the result of an inherited genetic mutation; and 3) a twin study showing that genetic contributions to common cancers are small and likely arise from rare mutations, not commonly occurring gene variants such as SNPs ( 7 ).
If the fi rst conclusion is drawn and larger gene -cancer association studies are undertaken, an important consideration is how small a relative risk would be worthwhile (in terms of net health benefi t) to detect. To put this question in perspective, one needs to consider the sequence of events leading to a worthwhile clinical benefi t: 1) the genetic variant must suggest a modifi able risk factor; 2) an intervention must be developed or identifi ed based on this modifi able risk factor; 3) the intervention must be tested in an extremely large randomized cancer prevention trial; and 4) there must be no side effects whose harms would outweigh the small benefi ts. It is important to realize that larger genecancer association studies to detect smaller relative risks yield diminishing net returns due to the larger cost of the gene identifi cation study, larger cost of the resulting cancer prevention trial, and smaller future clinical benefi ts compared to potential harms.
STUART G . BAKER

Response
We thank the correspondents for their comments. Ambrosone et al. suggest that our interpretation of our results repre sents a growing divergence in perspective between investigators with a statistical genetic viewpoint and those with a mole cular epidemiology viewpoint. We do not subscribe to this view. The Breast Cancer Association Consortium (BCAC) represents a wide spectrum of researchers, from statistical geneticists to clinical oncologists, and includes investigators who regard themselves as molecular epidemiologists. Moreover, in several respects, our interpretation of the data is not fundamentally different from that of Ambrosone et al. Our main conclusion was that for 11 of the 16 singlenucleotide polymorphisms (SNPs) tested there was no main effect, and that for the other five there was weak evidence for a main effect. We completely agree that susceptibility is likely to be the result of a complex interplay between genetic variation and environmental/lifestyle factors, and we did not rule out the possibility that such interactions may occur, either for these specific SNPs or for any other variants. Indeed, we stated that " … it is possible that these polymorphisms alter risk in subgroups of the population that have been exposed to specific environmental and lifestyle factors, for example, if an association of ADH1C I350V with breast cancer risk were limited to women with high alcohol consumption." Given that the main effect for any given risk factor is a weighted average of all possible interactions of that risk factor with other factors, we went on to state that " … where no main effect has been detected, such subgroup effects must be small, the at-risk subgroup must repre sent a small proportion of the population under study, or there must be true crossover effects (i.e., genotype associations of different direction among subgroups), which are unlikely." Moreover, because the number of possible interacting factors is very large the opportunities for type I statistical errors are greater, and even more stringent levels of statistical significance are required for subgroup and interaction analyses. Consequently, the power to detect a modest interaction effect is extremely small, even with large sample sizes such as in our dataset. Although the likelihood of detecting interactions may be increased by careful selection of the exposure of interest and the genetic variant(s), this approach is most likely to be productive where main effects have already been established for both the exposure and variant. This was the topic of earlier commentaries by several BCAC collaborators ( 1 , 2 ) .
The examples of interactions between environmental exposures and genotype cited by Ambrosone et al. are not directly relevant to the issue of performing underpowered subgroup/interaction analyses when there are no main effects. In the fi rst example ( 3 ), the putative interaction between the genetic variant of catalase (CAT-262 c>t) and fruit and vegetable consumption on catalase activity occurred when there was a statistically signifi cant main effect for both genotype and environmental factor. Similarly, the possible interaction between the glutathione peroxidase variant GPX1 P198L and alcohol consumption on catalytic activity of this enzyme occurred in the context of statis tically signifi cant main effects ( 4 ) .
We agree that, in general, heterogeneity of effects might be seen between studies because of differences in the prevalence of important interacting exposures. However, such differences are unlikely to explain the heterogeneity we observed for several SNPs, given that there were not substantial differences between the fi ndings of studies carried out in populations of Asian origin and those based on subjects of European descent.
Baker suggests that one conclusion that might be drawn from our data is that they "support other evidence of very weak, or no association between common genetic variants and cancer." This conclusion seems premature given that we have studied just 16 common variants out of several million across the genome, of which fi ve showed some evidence, albeit weak, of association. Several genome-wide association studies in breast cancer are ongoing, and over the next year or so, it should become clearer whether or not this conclusion is justifi ed. Baker additionally suggests that it is not worth detecting alleles with small effect, even if they do exist, because of their limited clinical signifi cance. We agree that the clinical signifi cance of individual markers is likely to be small. However, the combined effect of multiple alleles may well be substantial and of clinical importance ( 5 ). Furthermore, although practical ap plication in prevention is an important consideration, it is not the only justifi cation for such research. Important insights into cancer biology are likely to come from identifying novel genes, and these may have wider implications for prevention and cure beyond simply identifying individuals at high risk.
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